FDA Relaxes Safety Requirements For Alzheimer's Trials, But Uncertainty Persists
Executive Summary
Sponsors and contract research organizations expressed cautious optimism about FDA's adoption of some of the recommendations of the Alzheimer's Association Research Roundtable Workgroup, but the agency isn't specifying which recommendations it is accepting.
You may also be interested in...
Alzheimer’s Plan Emphasizes Acceleration, Sets Timeline On Prevention, Cure
Ambitious draft plan from the Obama administration includes public/private efforts to shorten drug development times and pick up the pace of clinical trials, including more efficient ways of identifying and enrolling participants.